Drugs / THDB0206
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07257627 | Apr → Dec 2024 | — | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 1 | NCT06153329 | Jun 2021 → Jun 2022 | — | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 32 trials | ||||||
| Phase 3 | NCT05834868 | May 2022 → Dec 2024 | type 2 diabetes mellitus | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
| Phase 3 | NCT07282054 | Apr 2022 → Jan 2025 | type 1 diabetes mellitus | Tonghua Dongbao Pharmaceutical Co.,Ltd | Completed | No outcome recorded |
News releases announcing trial results or a regulatory action · 3
| Date | Issuer | Release |
|---|---|---|
| 2026-06-08 | Adocia | Results ADOCIA Announces THDB0206 (BioChaperone® Lispro) Phase 3 Data in Type 2 Diabetes Presented at ADA 86th Scientific Sessions, Confirming the Positive Results Previously Announced in July 2025 adocia.com ↗ |
| 2025-10-15 | Adocia | Results ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in people with T1D adocia.com ↗
ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in people with T1D |
| 2025-07-25 | Adocia | Results ADOCIA and Tonghua Dongbao Announce Positive Topline Results of Phase 3 Clinical Trial on Ultra-Rapid Insulin BioChaperone® Lispro (THDB0206 injection) in people with T2D adocia.com ↗
Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical -stage biopharmaceutical company focused on the research and development of innovative therapeutic solutions for the treatment of diabetes and obesity , announces that its partner Tonghua Dongbao releases today positive topline results on the Phase 3 clinical trial on BioChaperone® Lispro (THDB0206 injection), a novel Ultra-Rapid Insulin formulation. |
All press releases naming this drug 3 releases
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | THDB0206 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07257627 ↗ |
| Route | Subcutaneous | “Injected subcutaneously three times a day.” NCT05834868 ↗ |